The US Army is testing a universal vaccine it hopes will target all coronavirus variants

The US Army is working on a vaccine that will target all existing coronaviruses.
According to a press release from the US Army Walter Reed Army Institute of Research, SpFN has shown promise in non-human primate trials and early human trial results are expected this month.
The jab could help protect against other coronaviruses beyond COVID-19.
A new design.

The vaccine is made on a new platform.

This shot would work by injecting a molecule that looks like a soccer ball, unlike most currently available vaccines, which use messenger musculus Ankara, or messenger musculus Ankara.

Each face of the ball has a small amount of spikeProtein that can cause the body to mount a protective immune response.

This allows scientists to attach the spikes of multiple coronaviruses strains on different faces of the "ball" so the body could protect against multiple variant at the same time.

Human results are coming soon, says the Army.

The shot could work against COVID-19 and other coronaviruses, according to the Army.

The original variant of the COVID-19 coronaviruses can cause disease in non-human primate.
The immune responses against Alpha, Delta, and other variants were triggered by two doses.

The Army said in a press release that the results from the very early trials of SpFN are expected to be released this month.
A vaccine is being developed against the next epidemic.

SpFN was able to cause a strong immune response against the relative of the COVID-19 coronaviruses that caused the 2002 and 2003 outbreak of the Severe Acute Respiratory Syndrome.

The hope is that this shot could be an effective vaccine for coronaviruses.

The Army is not the only institute that is developing designs. Future Pandemics are expected to be driven by other kinds of coronaviruses, so a vaccine could be useful to prevent them.

The emergence of human coronaviruses throughout the past two decades and the rise of SARS-CoV-2 variant, including most recently Omicron, underscore the continued need for next-generation preventative vaccines that confer broad protection against coronaviruses diseases.